

CQ15-3 (GRADE)

P: Septic DIC patients

I: Use of antithrombin

C: Use of placebo/ not use of antithrombin

O: Mortality, bleeding complication, resolution of DIC

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality												
5	randomised trials	not serious	not serious	not serious	serious	none	62/201 (30.8%)	86/193 (44.6%)	RR 0.70 (0.57 to 0.87)	134 fewer per 1,000 (from 192 fewer to 58 fewer)	⊕⊕⊕○ Moderate	CRITICAL
Bleeding complication												
3	randomised trials	not serious	not serious	not serious	very serious	none	8/158 (5.1%)	7/163 (4.3%)	RR 1.20 (0.45 to 3.19)	9 more per 1,000 (from 24 fewer to 94 more)	⊕⊕○○ Low	CRITICAL
Resolution of DIC												
3	randomised trials	not serious	not serious	not serious	serious	none	32/54 (59.3%)	8/55 (14.5%)	RR 3.39 (1.74 to 6.59)	348 more per 1,000 (from 108 more to 813 more)	⊕⊕⊕○ Moderate	IMORTANT

	JUDGEMENT						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know

CQ15-4 (GRADE)

P: Septic DIC patients

I: Use of heparin

C: Use of placebo/ not use of heparin

O: Mortality, bleeding complication, resolution of DIC

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality												
2	randomised trials	serious	not serious	not serious	very serious	none	12/127 (9.4%)	18/134 (13.4%)	RR 0.57 (0.26 to 1.20)	58 fewer per 1,000 (from 99 fewer to 27 more)	⊕○○○ Very low	CRITICAL
Bleeding complication												
1	randomised trials	serious	not serious	not serious	very serious	serious	5/105 (4.8%)	12/119 (10.1%)	RR 0.48 (0.16 to 1.27)	52 fewer per 1,000 (from 85 fewer to 27 more)	⊕○○○ Very low	CRITICAL
Resolution of DIC												
1	randomised trials	serious	not serious	not serious	serious	none	20/22 (91%)	6/15 (40%)	RR 0.11 (0.02 to 0.53)	356 fewer per 1,000 (from 392 fewer to 188 fewer)	⊕⊕○○ Low	IMORTANT

	JUDGEMENT						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know

CQ15-5 (GRADE)

P: Septic DIC patients

I: Use of thrombomodulin

C: Use of placebo/ not use of thrombomodulin

O: Mortality, bleeding complication, resolution of DIC

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality												
3	randomised trials	not serious	not serious	not serious	serious	none	156/725 (21.5%)	192/742 (25.9%)	RR 0.84 (0.70 to 1.01)	41 fewer per 1,000 (from 78 fewer to 3 more)	⊕⊕⊕○ Moderate	CRITICAL
Bleeding complication												
3	randomised trials	serious	not serious	not serious	serious	none	44/813 (5.4%)	34/820 (4.1%)	RR 1.30 (0.84 to 2.02)	12 more per 1,000 (from 7 fewer to 42 more)	⊕⊕○○ Low	CRITICAL
Resolution of DIC												
2	randomised trials	serious	not serious	not serious	serious	none	40/92 (43.5%)	27/95 (28.4%)	RR 1.45 (0.99 to 2.11)	128 more per 1,000 (from 3 fewer to 315 more)	⊕⊕○○ Low	IMORTANT

	JUDGEMENT						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know

CQ15-6 (GRADE)

P: Septic DIC patients

I: Use of protease inhibitor

C: Use of placebo/ not use of protease inhibitor

O: Mortality, bleeding complication, resolution of DIC

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality												
2	randomised trials	serious	not serious	not serious	very serious	none	14/45 (31.1%)	16/45 (35.6%)	RR 0.89 (0.49 to 1.61)	39 fewer per 1,000 (from 181 fewer to 217 more)	⊕○○○ Very low	CRITICAL
Bleeding complication												
1	randomised trials	serious	not serious	not serious	very serious	none	2/25 (8.0%)	6/25 (24.0%)	RR 0.33 (0.07 to 1.50)	161 fewer per 1,000 (from 223 fewer to 120 more)	⊕○○○ Very low	CRITICAL

	JUDGEMENT						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know